Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

139.44 -0.54 (-0.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,436,836
Open 139.66
Bid (Size) 139.27 (2)
Ask (Size) 139.44 (1)
Prev. Close 139.98
Today's Range 138.63 - 140.80
52wk Range 128.51 - 238.00
Shares Outstanding 145,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
From Biogen Inc.
Via GlobeNewswire
Indexes Swimming In Red Ink On Recession Fears
Stocks are looking to extend last week's losses, as recession fears grip Wall Street. 
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Economy

Performance

YTD
-7.04%
-7.04%
1 Month
+0.72%
+0.72%
3 Month
-7.34%
-7.34%
6 Month
-30.13%
-30.13%
1 Year
-36.42%
-36.42%

More News

Read More
How Is The Market Feeling About Biogen?
Via Benzinga
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
Via Benzinga
Biogen Analysts Lower Their Forecasts After Q4 Results
Via Benzinga
Forecasting The Future: 10 Analyst Projections For Biogen
Via Benzinga
Stocks Plummet As Trade Partners Retaliate Against Tariffs
Via Talk Markets
Topics Government Stocks / Equities World Trade
Exposures Political Tariff
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
Via StockStory
Synchronicity: Denying The Unexplainable
Via Talk Markets
Topics Stocks / Equities
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Via Benzinga
Biogen Stock Is Mutating Into a Value Play
Via MarketBeat
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Via Benzinga
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Biogen Inc.
Via GlobeNewswire
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
Via Benzinga
Top S&P500 movers in Wednesday's session
Via Chartmill
Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook
Via Benzinga
These S&P500 stocks have an unusual volume in today's session
Via Chartmill
These S&P500 stocks are moving in today's session
Via Chartmill
Biogen (BIIB) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Wednesday's session: gap up and gap down stock in the S&P500 index
Via Chartmill
Biogen Stock Slides To Fresh 12-Year Lows As Profit Outlook Misses, But Retail Snaps Up The Dip
Via Stocktwits
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
Via Benzinga
Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.